[Second-line treatment using novel chemotherapeutic and biologic agents]
1Dept. of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka, Japan.
Abstract:
The goal of therapy for recurrent cancer is to delay progression, relieve symptoms, and improve QOL. Cytotoxic agents combined with carboplatin for sensitive disease(TFIB6 months), and cytotoxic agents without cross-resistance to taxane/platinum against resistant diseases are required. There is a limit to improvement in efficacy by using cytotoxic agents, and a promising biological agent is expected to emerge while phase II studies of various biological agents continue. Regarding molecular-target drugs, only bevacizumab is confirmed to be effective at present, so it is used in monotherapy or combination therapy with anticancer drugs. In the GOG started a RCT of bevacizumab or placebo that was combined with TC regimen. Also in patients with chemo-sensitive disease, a RCT of TC regimen combined with or without bevacizumab started. In addition, EORTC and ICON trials of cediranib and erlotinib combined with platinum-based regimen are on-going.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers
Treatment Resistent Cancers

